For research use only. Not for therapeutic Use.
Nevanimibe（Cat No.:M118833）is a potent inhibitor of acyl-coenzyme A: cholesterol acyltransferase (ACAT), an enzyme critical in cholesterol metabolism and steroid biosynthesis. By inhibiting ACAT, Nevanimibe reduces cholesterol ester formation, which is particularly useful in treating conditions like Cushing’s syndrome and adrenal hyperplasia, where excess cortisol production is driven by cholesterol accumulation in adrenal tissues. Its targeted action on cholesterol metabolism makes Nevanimibe a promising candidate in endocrine research, offering potential therapeutic strategies for managing adrenal disorders and exploring novel cholesterol modulation pathways in metabolic health.
| Catalog Number | M118833 |
| CAS Number | 133825-80-6 |
| Molecular Formula | C27H39N3O |
| Purity | ≥95% |
| Target | Apoptosis |
| Storage | 2-8°C |
| IUPAC Name | 1-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]-3-[2,6-di(propan-2-yl)phenyl]urea |
| InChI | InChI=1S/C27H39N3O/c1-19(2)23-10-9-11-24(20(3)4)25(23)29-26(31)28-18-27(16-7-8-17-27)21-12-14-22(15-13-21)30(5)6/h9-15,19-20H,7-8,16-18H2,1-6H3,(H2,28,29,31) |
| InChIKey | PKKNCEXEVUFFFI-UHFFFAOYSA-N |
| SMILES | CC(C)C1=C(C(=CC=C1)C(C)C)NC(=O)NCC2(CCCC2)C3=CC=C(C=C3)N(C)C |
